MedTrace Logo

Atrasentan in Treating Patients With Prostate Cancer

NCT00046943 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2011-02-21

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.

Conditions

Interventions

DRUG

atrasentan hydrochloride

Sponsors & Collaborators

Principal Investigators

  • Gary Gordon, MD, PhD · Abbott

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00046943 on ClinicalTrials.gov